South Korea to cap generic and copy drug prices at 40% of originals
The South Korean government is moving to reform how drug prices are set, aiming to slash the prices of generic and copy medicines to about 40 percent of the price of the original drugs. The plan would apply to newly introduced generics and to existing generics that have not changed price since 2012, with some exceptions.
Officials say the current system leads to many copy drugs being sold at prices far above what is typical internationally. Korea has seen dozens of generic versions for single originals, and prices are reported to be about 2.17 times the OECD average. The reform intends to curb this by anchoring prices of new generics at roughly 40 percent of the original drug's price, down from about 53.5 percent under the current framework.
The changes would affect about 4,000 items already listed on the national price schedule, and would be implemented in phases beginning in the second half of this year. The government says the adjustments could reduce the National Health Insurance’s drug expenditures by around 1 trillion won, potentially lowering patient out-of-pocket costs.
The policy excludes medicines that are rare or require stable supply to ensure access, the Health Ministry noted. Health and Welfare Minister Jeong Eun-kyung said the price cuts are designed to preserve the sustainability of Korea’s National Health Insurance while also supporting a policy environment that rewards innovative R&D.
Pharmaceutical and bio industry groups have argued that the reform could lead to significant revenue losses, warning of up to 3.6 trillion won in annual sales reductions and the potential loss of about 14,000 jobs. They contend the changes could dampen Korea’s ability to invest in new drug development.
The government has pushed back on those warnings, pointing to a strong rise in research and development spending among listed pharmaceutical firms after past price adjustments. Officials cited that by 2023, R&D investment by these companies had increased substantially, arguing the new reform would not derail innovation.
Officials say the plan will proceed with its scheduled rollout after July, maintaining the commitment to implement the reform in the second half of the year. The government frames the move as a balance between making medicines more affordable for citizens and preserving incentives for future drug development.
Why this matters beyond Korea: Korea is a major Asian market with a sophisticated healthcare system and a large generic-drug sector. Shifts in Korean drug pricing can influence regional pricing dynamics, supply chains, and investment decisions by multinational pharmaceutical companies. For U.S. policymakers and markets, the reform highlights ongoing global debates over drug affordability, innovation incentives, and how public health financing interacts with private-sector R&D and competition in the pharmaceutical industry.